Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Medtronic
Boehringer Ingelheim
Moodys

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR EMTRICITABINE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Emtricitabine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00641641 ↗ The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection Completed Merck Sharp & Dohme Corp. N/A 2008-03-01 The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
New Combination NCT00641641 ↗ The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection Completed Kirby Institute N/A 2008-03-01 The purpose of this study is to measure the decay characteristics of HIV in the blood of patients after taking a combination of anti-HIV drugs, which includes a new class of anti-HIV drug, an integrase inhibitor. This study explores how this new combination of therapy reduces virus in various compartments of the body and immune system.
New Formulation NCT02583464 ↗ Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg. Completed Laboratorio Elea Phoenix S.A. Phase 1 2014-09-01 Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R) to meet regulatory criteria for marketing the test product in Argentina.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Emtricitabine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002335 ↗ The Safety and Effectiveness of 524W91 Completed Glaxo Wellcome Phase 1 1969-12-31 To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.
NCT00002362 ↗ A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Suspended Triangle Pharmaceuticals Phase 3 1999-08-01 This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
NCT00002416 ↗ Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination Completed Triangle Pharmaceuticals Phase 3 1969-12-31 The purpose of this study is to compare two anti-HIV drugs, FTC and lamivudine (3TC), when given with either stavudine (d4T) or zidovudine (ZDV) and one other anti-HIV drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Emtricitabine

Condition Name

Condition Name for Emtricitabine
Intervention Trials
HIV Infections 162
HIV 91
HIV-1 Infection 44
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Emtricitabine
Intervention Trials
HIV Infections 253
Acquired Immunodeficiency Syndrome 100
Infections 80
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Emtricitabine

Trials by Country

Trials by Country for Emtricitabine
Location Trials
Canada 166
Spain 117
France 114
South Africa 109
Germany 101
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Emtricitabine
Location Trials
California 137
Florida 114
Texas 107
New York 100
North Carolina 91
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Emtricitabine

Clinical Trial Phase

Clinical Trial Phase for Emtricitabine
Clinical Trial Phase Trials
Phase 4 155
Phase 3 123
Phase 2/Phase 3 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Emtricitabine
Clinical Trial Phase Trials
Completed 319
Recruiting 45
Unknown status 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Emtricitabine

Sponsor Name

Sponsor Name for Emtricitabine
Sponsor Trials
Gilead Sciences 138
National Institute of Allergy and Infectious Diseases (NIAID) 61
Merck Sharp & Dohme Corp. 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Emtricitabine
Sponsor Trials
Other 573
Industry 354
NIH 91
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
McKesson
Harvard Business School
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.